← Back

Wire · opportunities

Schizophrenia Drug Cut Hallucination and Delusion Scores in Alzheimer's Patients

Published

22 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medicaldaily.com →

◆ Verified

Fusion42 · 22 November 2026 · Fusion42 review

Bristol Myers Squibb's schizophrenia drug Cobenfy showed reductions in hallucinations and delusions scores in Alzheimer's patients during open-label Phase 3 trials, though placebo-controlled data is still pending and results are limited by lack of blinding. These findings highlight an urgent need for treatments of neuropsychiatric symptoms in Alzheimer's disease, with final efficacy data expected in 2027.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can pivot your drug development towards Alzheimer's hallucinations as a high-need area now proving drug impact, but final proof will require waiting for blinded trial results in 2027. Families seeking safer alternatives to antipsychotics create a ready market if you can demonstrate efficacy convincingly.

◆ Coverage

1 source · 22 Nov 2026

◆ Related on Wire

◆ Topics

Biotechalzheimersschizophrenia-drugphase-3-trialneuropsychiatric-symptomsopen-label